odium glucose cotransporter 2 (SGLT2) inhibitors are oral antidiabetic drugs that improve urinary excretion of glucose, in this way regulating glycemic control and promoting weight loss. 1 The mechanism of action of SGLT2 inhibitors is a blood sugar reduction independent of insulin.
Persistent Diuresis Associated Dapagliflozin Treatment
A AB BS ST TR RA AC CT T Diabetic ketoacidosis is a clinical entity characterized by high blood sugar, ketone positivity and high anion gap metabolic acidosis. In these patients; polyuria is commonly detected due to hyperglycemia. Polyuria-induced dehydration may even be seen, especially in elderly patients. Polyuria is not expected to continue after hyperglycemia has resolved. We reported in this article; a 55 years old man with type-2 diabetes mellitus who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (dapagliflozin) who developed diabetic ketoacidosis and persistent diuresis in the post-treatment normoglycemic period. Table  1 . His blood count revealed neutrophil-induced leukocytosis. Empirical ceftriaxone therapy was started for urinary tract infections. No recurrence was detected in the urine culture from the patient. Daily glycosuria didn't follow up.
The patient's oral antidiabetic agent was discontinued cause of diabetic ketoacidosis. At first implemented isotonic saline added sodium bicarbonate and a continuous insulin infusion. Aggressive sodium bicarbonate therapy was given because the pH was at a level that was inconsistent with life. In the patient's follow up; 5% dextrose infusion was added to the patient because his acidosis did not improve even though his blood sugar was <200 mg/dL. The next day the urea and creatinin values declined to normal levels. The infusion of dextrose and saline with sodium bicarbonate continued because the patient had resistant acidosis. On the 2 nd day of hospitalization metabolic acidosis improved, delirium clinic retreated and oral nutrition was initiated. Therefore the basal bolus regimen was switched from insulin infusion therapy. Excessive urination since the patient's hospitalization was continued despite the provision of normoglycemia. Therefore, oral fluid intake of the patient was restricted. Despite the restriction of oral fluid intake, the patient's polyuria continued and there was Ahmet 7000 ml of urine output. In Figure 1 , the patient's oral fluid intake and urine output were showed. Patient's oral fluid intake restricted on the fourth day of treatment cause of polyuria, even so urine output was not reduced. Glycosuria continued from the first day of hospitalization to discharge; although blood sugar decline to normal levels on second day. On the 10 th day of hospitalization, the patient was discharged with basal bolus insulin regimen. The patient did not come to polyclinic control.
DISCUSSION
SGLT-2 inhibitors, the first member of dapagliflozin; have been widely used in the treatment of Type-2 diabetes mellitus. Various previous studies have shown that; the effect of blood sugar reducing of SGLT-2 inhibitors is due to inhibition of glucose reabsorption at the kidney level. 7, 8 Depending on this polyuria develops and may lead to dehydration. This effect is clearly demonstrated in a study of rats with dapagliflozin. 9 Canagliflozin is another member of SGLT-2 inhibitors. In a recent case report; patient has euglycemic acidosis and polyuria occurring whose receiving canagliplozin treatment has been discussed. According to this case report there is still ongoing polyuria even after the patient has had euglycemia. 6 In another previous study shown that, polyuria was continued even after 11 days of discontinuation of SGLT-2 inhibitors. 10 In our case on the 7 th day of treatment, the serum glucose measurement was 96 mg/dL, therefore the urine measurement showed +++ glycosuria. In our case that we have presented; there was a polyuria that did not respond to oral fluid restriction. polyuria that does not respond to oral fluid restriction; may be the effect of dapagliflozin due to nephrogenic or central diabetes insipidus enhancer. The findings of this case emphasize that; SGLT-2 inhibitors may cause severe diabetic ketoacidosis, persistant polyuria and dehydration.
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